Lab2Market Launch Health Closing Ceremony
Come celebrate the culmination of Lab2Market Launch Health 2026 with us!
The Schedule is as follows:
12:00pm
Companies will pitch in the following order. Please come ready to listen into their 5 minute pitches and ask your questions!
Parizad Katila - Oligomaster is a biotech company focused on improving wound care for patients suffering from chronic wounds. We are developing an injectable hydrogel wound dressing technology derived from natural materials that conforms to wound geometry upon application, maintaining an ideal healing environment while minimizing patient discomfort and reducing dressing change frequency. With rising rates of diabetes and aging populations driving demand for more effective wound care solutions, Oligomaster aims to address a critical gap in the market by offering a naturally derived alternative to current standard dressings that fail to support optimal healing conditions.
Bren Kugamoothy - Elev8 is a wearable robotic joint health platform. The company team is comprised of scientist’s, founders and athletes affiliated with Harvard, NBA, and Olympics. The patent pending device combines targeted recovery interventions with real-time wellness treatment, monitoring to improve load tolerance, performance, and long-term joint function.
Mazhar Shahen - NewGen Health helps clinicians continuously screen patients between visits, catching conditions like preeclampsia and chronic kidney disease weeks earlier than traditional in-office testing. Our platform combines a multi-biomarker device kit with RPM software, giving clinicians real-time patient data without adding chair time.
Mobina Mobaraki - SONA is a Canadian AI scribe built for mental health therapists in private practice, helping reduce burnout caused by up to 33 hours of unpaid monthly note-taking. It passively listens during sessions without storing audio and generates a complete clinical case note in the therapist’s own writing style, improving over time through feedback. We already have a paying customer who referred us to a 10-location applied behaviour analysis clinic.
Mostafa Javaheri - LigandQI helps drug discovery teams identify weak interactions in drug candidates by analyzing how they bind to target proteins. It provides deeper insight into binding quality, helping researchers understand why a compound may succeed or fail. This enables better decision making early in development and reduces the risk of costly failures.
Hamza Elkahim - NeviSight is an AI-powered clinical decision support tool that helps eye care providers detect and risk-stratify choroidal nevi using standard fundus images taken during routine eye exams. By combining deep learning classification with lesion segmentation, NeviSight reduces unnecessary specialist referrals and enables earlier detection of high-risk cases, with an OEM licensing model targeting fundus camera manufacturers.
Olga Klushina - Oculum is a medtech company focused on improving the safety and quality of ophthalmic surgery. The company’s mission is to reduce reliance on surgical dyes and other adjuncts that can introduce added risk, side effects, and workflow burden in the operating room. By enabling surgeons to better visualize critical tissue during procedures, Oculum aims to help eliminate chemical staining while supporting more consistent surgical outcomes. Its approach is grounded in real clinical needs and designed to fit naturally into existing surgical practice.
Manak Bajaj - Wonderguard is building an AI-powered smart catheter adaptor that helps hospitals detect infection earlier through real-time monitoring. It combines low-cost biosensors and predictive analytics to improve patient care and reduce hospital-acquired infections.
Marie-Claire Wassan - Oncolinc Therapeutics is a cancer therapeutics company addressing one of oncology’s most urgent challenges: up to 70% of patients do not respond to current immunotherapies. The company is developing first-in-class therapies that target immunosuppressive long non-coding RNAs (lncRNAs) to restore the ability of immune cells to eliminate tumors, extending the survival and quality of life of cancer patients.